Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy
about
Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor CellsAntibody-drug conjugates as novel anti-cancer chemotherapeuticsHypothesis: primary antiangiogenic method proposed to treat early stage breast cancerGenetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophagesInhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins.Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma.Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models.Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition.Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles.Normal and abnormal pulmonary arteriovenous shunting: occurrence and mechanisms.Advances and challenges in developing cytokine fusion proteins as improved therapeutics.The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering.Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model.AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer.Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis.Inhibition of Corneal Neovascularization by Subconjunctival Injection of Fc-Endostatin, a Novel Inhibitor of AngiogenesisBioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin.
P2860
Q26766481-18FD1FB2-8524-41B7-AC91-3A3CDB92D82EQ26800175-461374B5-D49B-4E6B-87E2-4038033F74D0Q33398689-DDB5D8F6-78AD-4F5C-B6C3-0C2AEC858904Q33592796-6FD8D562-6DA6-4569-B5FB-9C56C0C5681CQ34632979-78F60EB4-8139-440A-A432-FA30D1F1DAD7Q35164399-884479D1-9D6D-4C71-9D6B-6857B54A8620Q35740177-14CB4A68-0C0E-45DA-9985-BDBFDE77F2BEQ35813114-3CFC2173-BB79-444E-B31A-3623684B118EQ36094099-7D218C9A-22B0-4F2D-A691-8762532366C3Q36220259-62B1974A-3957-400F-B660-CE0E5E9A099AQ36881812-1C39E115-C5BC-4FF1-A0E5-16A9078C3F92Q37947579-5CDD9CE6-B557-44FB-9805-B204046D435AQ38086269-8661C23B-F219-4C04-BBC8-9436C3CF493EQ38088357-9023F11A-65CF-4168-B40E-31C5F41198C2Q39308829-D94005A4-A692-4E36-9D88-C2AE33258DC3Q39391503-1F13875B-2D42-41AE-BEAA-96D858ACED01Q39655433-456490C6-35B7-402B-9AB9-352AFE86991AQ41556287-FB7C44BF-14D1-42FB-9D7A-52E8CFAFEC91Q42124371-15D60AB7-DF8C-43D9-BE20-5709D60D17E5Q46292754-E2B24CE4-485C-4B51-924A-50C6E290AFFC
P2860
Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Linking antibody Fc domain to ...... ostatin half-life and efficacy
@ast
Linking antibody Fc domain to ...... ostatin half-life and efficacy
@en
Linking antibody Fc domain to ...... ostatin half-life and efficacy
@nl
type
label
Linking antibody Fc domain to ...... ostatin half-life and efficacy
@ast
Linking antibody Fc domain to ...... ostatin half-life and efficacy
@en
Linking antibody Fc domain to ...... ostatin half-life and efficacy
@nl
prefLabel
Linking antibody Fc domain to ...... ostatin half-life and efficacy
@ast
Linking antibody Fc domain to ...... ostatin half-life and efficacy
@en
Linking antibody Fc domain to ...... ostatin half-life and efficacy
@nl
P2093
P1476
Linking antibody Fc domain to ...... ostatin half-life and efficacy
@en
P2093
Bissan Ahmed
Elke A Pravda
Judah Folkman
Kashi Javaherian
Kin-Ming Lo
Robert M Tjin Tham Sjin
Shahla Movahedi
Stephen D Gillies
Tong-Young Lee
P304
P356
10.1158/1078-0432.CCR-07-1530
P407
P577
2008-03-01T00:00:00Z